INS and type 2 diabetes mellitus: Despite the controversies regarding the use of insulin and cancer risk, in a randomized clinical trial, the ORIGIN (Outcomes Reduction with an Initial Glargine Intervention) study, early treatment with insulin glargine in patients with dysglycemia, including pre-diabetes and type 2 diabetes, was not associated with increased cancer risk [25].